Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 1.30
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.10 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.35
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

4 Aug 2021 16:41

RNS Number : 6116H
Shield Therapeutics PLC
04 August 2021
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APMDZGGRKDMGMZM

Date   Source Headline
23rd May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
22nd May 20231:25 pmRNSForm 8.3 - Shield Therapeutics PLC
19th May 20234:17 pmRNSForm 8.3 - Shield Therapeutics Plc
19th May 20232:29 pmRNSForm 8.3 – Shield Therapeutics plc
19th May 20237:00 amRNS2022 Annual Report and 2023 AGM Notice
18th May 20233:15 pmRNSForm 8 (OPD) - Shield Therapeutics plc
18th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 20237:15 amEQSHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions
16th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
11th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
10th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 20235:20 pmRNSForm 8 (OPD) - Shield Therapeutics plc
9th May 20234:00 pmRNSRule 2.9 Announcement and TVR Update
9th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 202311:04 amGNWForm 8.3 - Shield Therapeutics plc
5th May 20233:09 pmRNSForm 8 (DD) - Shield Therapeutics Plc
5th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
5th May 202311:55 amRNSForm 8.3 - SHIELD THERAPEUTICS PLC
4th May 20232:40 pmRNSAOP Loan Conversion and Mandatory Cash Offer
27th Apr 20237:00 amRNSBusiness Update and Unaudited Results
12th Apr 20237:00 amRNSNotice of Results
5th Apr 20237:00 amRNSAppointment of Chief Commercial Officer
31st Mar 20237:00 amRNSBlock Listing 6 Monthly Return
15th Mar 20234:35 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTotal Voting Rights Update
17th Feb 202311:05 amRNSSecond Price Monitoring Extn
17th Feb 202311:00 amRNSPrice Monitoring Extension
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSFull Year Trading Update
23rd Jan 202311:15 amEQSHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
13th Jan 202310:30 amRNSHolding(s) in Company
13th Jan 20237:16 amEQSHardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability
12th Jan 20232:40 pmRNSHolding(s) in Company
12th Jan 20232:15 pmRNSHolding(s) in Company
9th Jan 20235:10 pmRNSPartial AOP Loan Conversion
9th Jan 20233:56 pmRNSHolding(s) in Company
9th Jan 20233:25 pmRNSHolding(s) in Company
5th Jan 20233:45 pmRNSResult of General Meeting & Open Offer
28th Dec 20227:00 amRNSTotal Voting Rights Update
28th Dec 20227:00 amRNSPDMR Transaction Notification
16th Dec 20227:00 amRNSPublication of Circular &Notice of General Meeting
13th Dec 20223:45 pmRNSSuccessful completion of US$18.5m Equity Fundraise
13th Dec 20227:02 amRNSInvestor presentation
13th Dec 20227:01 amRNSPlacing & Subscription to raise approx. US$18m
13th Dec 20227:00 amRNSCollaborative Sales Agreement signed with Viatris

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.